Hermetica Superfood Encyclopedia
The Short Answer
Alstonia congensis contains indole alkaloids—including echitamine and picrinine—as principal bioactive constituents that exert antispasmodic, vasodilatory, and antiplasmodial effects through adrenergic receptor modulation and inhibition of Plasmodium parasite growth. Stem-bark extracts demonstrated antispasmodic activity with IC50 values of 1.05–1.15 mg/mL in preclinical models, and the genus has shown antiplasmodial and anti-inflammatory activities in vitro, though human clinical validation for A. congensis specifically remains absent.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordAlstonia congensis benefits
Alstonia congensis — botanical close-up
Health Benefits
**Antimalaria Activity**: Indole alkaloids in A
congensis bark, particularly echitamine-type compounds, have shown antiplasmodial properties in vitro by disrupting Plasmodium falciparum metabolic processes, consistent with its traditional Yoruba use against malaria fevers.
**Antihypertensive and Vasodilatory Effects**
Stem-bark extracts exhibit vasodilatory activity partially attributed to β2-adrenergic receptor agonism, which promotes smooth muscle relaxation in vascular walls and may contribute to blood pressure reduction observed in ethnomedicinal practice.
**Antispasmodic Activity**
Ethanolic and aqueous stem-bark extracts demonstrated significant antispasmodic effects with IC50 values of 1.05–1.15 ± 0.1–0.8 mg/mL in isolated smooth muscle preparations, suggesting utility in managing gastrointestinal cramping and bronchospasm.
**Anti-inflammatory Properties**
Phytochemicals including flavonoids and terpenoids from A. congensis suppress pro-inflammatory mediator pathways, reducing cyclooxygenase activity and cytokine release in preclinical inflammatory models consistent with the broader Alstonia genus pharmacology.
**Antioxidant Activity**
Phenolic compounds and flavonoids in leaf extracts—where alkaloid concentrations reach 65.7 ± 1.0 mg/g—contribute to free radical scavenging, reducing oxidative stress markers in cell-based assays.
**Antibacterial and Antifungal Effects**
Bark and leaf extracts inhibit the growth of several Gram-positive and Gram-negative bacteria as well as fungal pathogens, with bioactivity attributed to the combined action of indole alkaloids and phenolic constituents disrupting microbial membrane integrity.
**Analgesic Properties**
Consistent with the genus-wide pharmacological profile, alkaloid fractions from A. congensis display analgesic effects in rodent pain models, likely through modulation of central and peripheral pain pathways including opioid-adjacent signaling.
Origin & History
Natural habitat
Alstonia congensis is a medium-to-large deciduous tree native to the tropical rainforests of West and Central Africa, with a documented range spanning Nigeria, Cameroon, Ghana, the Democratic Republic of Congo, and surrounding regions. It thrives in humid lowland forests, riverine margins, and forest edges at low to mid elevations, tolerating well-drained lateritic soils with high rainfall. The tree has not been widely cultivated commercially and is primarily harvested from wild stands, with bark, leaves, roots, and latex all utilized by local communities.
“Alstonia congensis occupies a significant place in the ethnomedicine of West and Central African communities, where the tree is widely recognized and used by Yoruba healers in Nigeria for the management of malaria and hypertension, with the bark being the most commonly employed plant part prepared as a decoction or cold infusion. Across the Congo Basin and adjoining forest regions, the latex of the tree has been applied topically to treat skin infections, wounds, and inflammatory conditions, reflecting a broad spectrum of ethnomedicinal applications rooted in centuries of empirical observation. The Alstonia genus, to which A. congensis belongs, holds cross-cultural medicinal significance from Africa through South and Southeast Asia, where related species such as A. scholaris and A. boonei have generated overlapping traditional therapeutic claims including febrifuge, analgesic, and tonic uses. Documentation of A. congensis-specific traditional uses has been captured primarily through ethnobotanical surveys conducted in Nigeria, Ghana, and Cameroon from the late twentieth century onward, forming the primary rationale for current scientific investigation.”Traditional Medicine
Scientific Research
The evidence base for Alstonia congensis consists almost entirely of in vitro assays and preliminary in vivo rodent studies, with no published randomized controlled trials in humans identified in the current literature. Preclinical studies have quantified antispasmodic IC50 values (1.05–1.15 mg/mL) and measured alkaloid content in leaf extracts (65.7 ± 1.0 mg/g), providing reproducible phytochemical benchmarks, but these do not constitute clinical proof of efficacy. The broader Alstonia genus is better characterized, with isolated compounds such as angustilongine A and B showing cytotoxic IC50 values of 0.3–8.3 μM against multiple human cancer cell lines (KB, PC-3, MCF7, HT-29, A549), yet it is not established whether A. congensis specifically produces these compounds in therapeutically relevant concentrations. Systematic reviews of the genus emphasize that species-specific and solvent-dependent variability in bioactivity is a major limitation, and mechanistic and clinical validation studies remain urgently needed before therapeutic claims for A. congensis can be substantiated.
Preparation & Dosage
Traditional preparation
**Decoction (Traditional)**
100–200 mL taken 1–2 times daily, though no standardized dose has been validated clinically
Bark is boiled in water for 15–30 minutes; typical traditional volumes range from .
**Aqueous Extract (Research Grade)**
100–500 mg/kg body weight in rodents; human-equivalent doses are not established and direct extrapolation is not recommended
Used in preclinical models at concentrations approximating .
**Ethanolic Extract**
15 mg/mL was determined in isolated tissue, not in vivo
Prepared via maceration or Soxhlet extraction of dried bark or leaves; the effective antispasmodic IC50 of 1.05–1..
**Leaf Infusion**
0 mg/g dried weight, though bioavailability via oral infusion is unknown
Leaves are steeped in hot water and consumed as a tea in some regional traditions; alkaloid content in leaves measured at 65.7 ± 1..
**Maximum Preclinical Dose Note**
210 mg/kg has been cited as a maximum effective dose, with toxic manifestations observed at 240 mg/kg; these figures should not be extrapolated to humans without formal pharmacokinetic and toxicological studies
In animal models, .
**Standardization**
No commercial standardized extract with defined alkaloid percentage currently exists for A. congensis.
Nutritional Profile
Alstonia congensis is not consumed as a food source and does not provide meaningful macronutrient or micronutrient nutrition in the conventional dietary sense. Its pharmacological relevance derives from secondary metabolites: alkaloid concentrations in leaf material have been quantified at 65.7 ± 1.0 mg/g, with indole alkaloids including echitamine and picrinine as the most pharmacologically characterized representatives. Flavonoids, terpenoids, phenolic compounds, and glycosides are present across bark, leaf, and root tissues, with phenolic content contributing to measured antioxidant capacity in DPPH and FRAP assays, though precise concentrations vary with geographic source, tissue type, harvest season, and extraction solvent. Bioavailability of these phytochemicals in humans is unstudied; lipophilic alkaloids and terpenoids are expected to have moderate oral absorption based on physicochemical properties, while polar glycosides may be subject to significant first-pass metabolism.
How It Works
Mechanism of Action
The primary mechanistic action of Alstonia congensis is attributed to its indole alkaloid fraction, particularly echitamine and picrinine, which interact with β2-adrenergic receptors to induce smooth muscle relaxation and vasodilation, directly relevant to its antihypertensive and antispasmodic properties. Antiplasmodial activity is hypothesized to involve inhibition of heme polymerization within the Plasmodium digestive vacuole—a mechanism shared by several Alstonia genus alkaloids—thereby causing toxic free heme accumulation in the parasite. Flavonoid and terpenoid constituents modulate cyclooxygenase (COX) enzymes and suppress nuclear factor-kappa B (NF-κB) transcriptional activity, reducing downstream synthesis of prostaglandins and pro-inflammatory cytokines including TNF-α and IL-6. Phenolic compounds contribute to antioxidant activity through direct hydrogen atom transfer and electron donation to reactive oxygen species, complementing the alkaloid-driven pharmacology across multiple organ systems.
Clinical Evidence
No human clinical trials specifically investigating Alstonia congensis have been identified in the peer-reviewed literature as of the current date. Available preclinical data demonstrate antispasmodic, antiplasmodial, and vasodilatory activities in isolated tissue and rodent models, but effect sizes, therapeutic windows, and human pharmacokinetics are entirely uncharacterized. Traditional ethnomedicinal use among Yoruba communities in Nigeria for malaria and hypertension represents the primary real-world evidence, which, while consistent with observed preclinical activities, cannot substitute for controlled clinical investigation. Confidence in therapeutic outcomes for human populations remains very low, and clinical translation requires dose-finding, safety, and efficacy trials before any conclusions can be drawn.
Safety & Interactions
Specific human safety data for Alstonia congensis are absent from the published literature, representing a critical gap; the only available toxicity benchmarks come from animal models, where extract doses at 240 mg/kg produced toxic manifestations and 210 mg/kg was identified as the maximum effective dose, but these figures cannot be reliably converted to human-equivalent doses without validated allometric scaling and pharmacokinetic data. Given the presence of potent indole alkaloids with adrenergic receptor activity, clinically significant interactions with antihypertensive agents (beta-blockers, calcium channel blockers, ACE inhibitors), antiarrhythmics, and antimalarial drugs such as chloroquine or artemisinin-based therapies are plausible and should be considered a theoretical risk. Alkaloid-containing plant preparations are generally contraindicated in pregnancy and lactation due to potential uterotonic and fetal developmental effects, and A. congensis should be avoided in these populations in the absence of safety data. Individuals with hepatic impairment, renal insufficiency, or those taking cytochrome P450-metabolized medications should exercise particular caution, and use without qualified medical supervision is not recommended.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Alstonia congensis Engl.pattern woodbroad-leaved alstoniaahun (Yoruba)egbu (Igbo)
Frequently Asked Questions
What is Alstonia congensis used for traditionally?
Alstonia congensis is used traditionally in West African ethnomedicine, most notably among Yoruba communities in Nigeria, for the management of malaria and hypertension, primarily as a bark decoction. The leaves, roots, and latex are also employed topically for wound healing, skin infections, and fever reduction across various Central and West African communities.
What are the active compounds in Alstonia congensis?
The principal bioactive constituents are indole alkaloids—including echitamine and picrinine—which are responsible for documented antispasmodic, antiplasmodial, and vasodilatory activities. Leaf extracts contain alkaloids at a concentration of approximately 65.7 ± 1.0 mg/g, alongside flavonoids, terpenoids, phenolic compounds, and glycosides that contribute anti-inflammatory and antioxidant effects.
Is there clinical trial evidence supporting Alstonia congensis for malaria?
No human clinical trials for Alstonia congensis have been published; all available evidence is derived from in vitro antiplasmodial assays and rodent studies. While preclinical data show promising antiplasmodial activity consistent with traditional use, clinical efficacy and safe dosing in humans remain entirely unestablished.
What is the safe dosage of Alstonia congensis?
No validated human dosage exists for Alstonia congensis. Preclinical animal studies identified a maximum effective dose of approximately 210 mg/kg body weight, with toxic effects appearing at 240 mg/kg, but these values cannot be directly translated into human doses without formal pharmacokinetic research. Use without medical supervision is strongly discouraged.
Are there any drug interactions or safety concerns with Alstonia congensis?
Due to its β2-adrenergic receptor activity, Alstonia congensis theoretically interacts with antihypertensive drugs, beta-blockers, and antimalarial medications including chloroquine, potentially causing additive or opposing cardiovascular effects. It is contraindicated in pregnancy and lactation given the potency of its alkaloid profile, and individuals on CYP450-metabolized medications should avoid it until drug interaction studies are conducted.
What form of Alstonia congensis is most effective for antimalaria benefits?
Bark extracts, particularly standardized preparations containing indole alkaloids like echitamine, have demonstrated the strongest antiplasmodial activity in research against Plasmodium falciparum. Aqueous and ethanolic extracts of the stem bark appear to preserve the active compounds better than whole plant preparations, making concentrated extracts preferable for malaria-related applications. The bioavailability of alkaloid compounds is optimized in extract forms rather than raw dried bark.
Is Alstonia congensis safe for use during pregnancy or while breastfeeding?
There is insufficient clinical safety data on Alstonia congensis use during pregnancy and breastfeeding, so it is generally recommended to avoid supplementation during these periods as a precautionary measure. The alkaloid content and potential uterine effects have not been adequately studied in pregnant or nursing populations. Consultation with a healthcare provider is essential before use in these sensitive life stages.
How does Alstonia congensis compare to other traditional antimalarial herbs in terms of potency?
Alstonia congensis shows in vitro antiplasmodial activity comparable to other West African antimalarial ethnobotanicals, with its echitamine-type alkaloids offering a distinct mechanism of action through metabolic disruption of Plasmodium parasites. Unlike some traditional herbs, A. congensis also exhibits vasodilatory and antihypertensive properties that may provide additional cardiovascular benefits beyond antimalarial effects. Direct clinical head-to-head comparisons with other antimalarials remain limited in peer-reviewed literature.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w alstonia-congensis-alstonia-congensis-engl curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
